Strategic collaboration aims to advance early cancer detection and precision oncology through AI-powered liquid biopsy solutions
1Cell.Ai has announced a strategic partnership with AccuGenomics to expand access to ultra-sensitive liquid biopsy testing across Asia. This collaboration combines advanced genomic diagnostics with artificial intelligence to enable earlier detection of cancer and more precise treatment monitoring.
Through this partnership, AccuGenomics will leverage 1Cell.Ai’s proprietary AI-driven analytical capabilities to enhance the sensitivity and accuracy of circulating tumor DNA (ctDNA) detection. The integration of these technologies is expected to significantly improve the identification of minimal residual disease (MRD) and enable real-time tracking of tumor dynamics.
Liquid biopsy has emerged as a transformative approach in precision oncology, offering a non-invasive alternative to traditional tissue biopsies. By detecting tumor-derived genetic material in blood samples, clinicians can make faster, more informed decisions regarding diagnosis, prognosis, and treatment strategies. The addition of AI-driven insights further strengthens the clinical utility of these tests by uncovering patterns that may otherwise go undetected.
The collaboration will initially focus on expanding access to advanced liquid biopsy solutions across key Asian markets, with plans to scale into additional regions, including the United States. By combining regional expertise in diagnostics with cutting-edge AI infrastructure, the partnership aims to bridge gaps in cancer detection and bring next-generation technologies closer to patients and healthcare providers.
Leaders from both organizations emphasized the importance of this collaboration in accelerating innovation within oncology. The partnership reflects a shared commitment to improving patient outcomes through early detection, personalized treatment strategies, and continuous disease monitoring.
About 1Cell.Ai
1Cell.Ai is a precision oncology company leveraging artificial intelligence to enhance cancer diagnostics and enable more personalized treatment approaches. Its platform focuses on extracting meaningful insights from complex biological data to support early detection and improve clinical decision-making.
About AccuGenomics
AccuGenomics specializes in advanced molecular diagnostics, delivering high-sensitivity genomic testing solutions to support cancer detection, monitoring, and research.
Media Coverage
This announcement has also been featured by external media: